C
Chenglong Han
Researcher at Janssen Pharmaceutica
Publications - 72
Citations - 2951
Chenglong Han is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Golimumab & Placebo. The author has an hindex of 22, co-authored 61 publications receiving 2554 citations. Previous affiliations of Chenglong Han include Oregon Health & Science University & Johnson & Johnson.
Papers
More filters
Journal Article
Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
TL;DR: Cardiovascular diseases and their risk factors were more common in patients with RA, PsA, and AS than in matched controls and use of selected cardiovascular medications was significantly higher in patients than controls.
Journal ArticleDOI
Predictors of joint damage in patients with early rheumatoid arthritis treated with high‐dose methotrexate with or without concomitant infliximab: Results from the ASPIRE trial
Josef S Smolen,Désirée van der Heijde,E. William St. Clair,Paul Emery,Joan M. Bathon,Edward C. Keystone,Ravinder N. Maini,Joachim R. Kalden,Michael Schiff,Daniel Baker,Chenglong Han,J. Han,Mohan Bala +12 more
TL;DR: High CRP level, high ESR, or persistent disease activity was associated with greater radiographic progression in the group taking MTX alone, while little radiography progression was seen in patients receiving both MTX and infliximab, regardless of the abnormal levels of these traditional predictors.
Journal ArticleDOI
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade
Josef S Smolen,Chenglong Han,D. van der Heijde,Paul Emery,Joan M. Bathon,E.C. Keystone,R N Maini,J. R. Kalden,Daniel Aletaha,David Baker,J. Han,Mohan Bala,E W St Clair +12 more
TL;DR: With methotrexate, joint damage progresses even at low and moderate disease activity levels, whereas methotRexate plus infliximab inhibits radiographic progression across all disease activity states, according to a direct relationship between disease activity and radiographic changes.
Journal ArticleDOI
Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial
Richard G. Langley,Steven R. Feldman,Chenglong Han,Brad Schenkel,Philippe Szapary,Ming Chun Hsu,Jean Paul Ortonne,Kenneth B. Gordon,Alexa B. Kimball +8 more
TL;DR: Patients receiving ustekinumab reported significant improvements in symptoms of anxiety, depression, and HRQoL.
Journal ArticleDOI
Infliximab treatment maintains employability in patients with early rheumatoid arthritis
Josef S Smolen,Chenglong Han,Désirée van der Heijde,Paul Emery,Joan M. Bathon,Edward C. Keystone,Joachim R. Kalden,Michael Schiff,Mohan Bala,Daniel Baker,J. Han,Ravinder N. Maini,E. William St. Clair +12 more
TL;DR: Patients with early RA who were treated with MTX plus infliximab had a higher probability of maintaining their employability compared with those who were diagnosed with early rheumatoid arthritis alone.